The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

1st NCRI AML academy meeting | Can the new treatments for AML reduce the need for allo-HSCT?

Sep 24, 2019

During the 1st NCRI AML academy meeting, the AML Global Portal was pleased to speak to Dr Mike Dennis from the Christie NHS Foundation Trust, Manchester, UK, who discussed how the new therapies that are now licensed for the treatment of AML may reduce the need for allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Can the new treatments for AML reduce the need for allo-HSCT?